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treated with antibiotics were excluded. Analysis was restricted to those patient visita-
tion cared by physician specialty with general practice, family practice, and internal 
medicine. Multivariate logit regression analysis was performed to assess the relation-
ship between patient insurance status and the prescribing of broad-spectrum antibiot-
ics controlling for age, gender, race and ethnicity, physician specialty, and 
comorbidities. RESULTS: Of 851 adults patients care for ARTI, 38% were prescribed 
one or more broad-spectrum antibiotics. In multivariate regression analysis, compared 
to those with private insurance, those with Medicaid, a public insurance program for 
low-income Americans, was associated with lower likelihood of prescribing of broad-
spectrum antibiotics (adjusted odds ratio (OR) 0.496, p = 0.003), so were those 
without health insurance (adjusted OR 0.499, p = 0.028), and those with Medicare, 
a public insurance program for the elderly or disabled adults (adjusted OR 0.666, p 
= 0.091). CONCLUSIONS: In the case of ARTI, those with private insurance were 
substantially more likely to be prescribed with broad-spectrum antibiotics, where the 
society may be better off if such overuse of antibiotics could be reduced.
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INTEGRATED EDUCATIONAL PROJECT WITH INDIVIDUAL FEEDBACK 
FROM CLAIMS DATA LEADS TO IMPROVED ANTIBIOTIC 
PRESCRIPTION AND RESISTANCE DECREASE
Hupkova H1, Foltan V2, Hroncova D3, Gezo M1
1General Health Insurance Fund, Bratislava, Slovak Republic, 2Comenius University, Bratislava, 
Slovak Republic, 3Mediforum, Non-commercial Educational Center of GSK, Bratislava, Slovak 
Republic
OBJECTIVES: Increasing antibiotics costs and resistance led to establishment of 
educational project S-MedDial under guarantee of the General Health Insurance Fund 
and related professional associations. The project evaluates prescription habits in 
respiratory infections, monitors antibiotics resistance and provides individual feedback 
to pediatricians. Introduction of new indexes and summary quality bar from selected 
eight indexes has enhanced comparison among physicians and their willingness to 
improve. METHODS: In the last round of the project the antibiotic prescription was 
analyzed for 97 doctors in 7 Slovak regions based on the retrospective claims data 
from September 2007 to March 2008 and compared with previous season data. 
Individual feedback was provided to practitioners during regional meetings together 
with expert presentations and educative leaﬂets. RESULTS: Every second child with 
respiratory infection was treated with antibiotics. The most frequent drugs in DDD 
were macrolides (22.6%), followed by beta-lactamase sensitive penicillins (19.5%) 
and cephalosphorines (18.4%). Best pediatricians (20% of the group) were signiﬁ-
cantly different compared to the rest in majority of the quality bar indexes: less 
patients treated with ATB (31% vs. 51%); lower proportion of ATB in treatment (in 
EUR: 51% vs. 73%, in DDD: 28% vs. 51%); lower ATB costs per patient (−15%); 
lower aminopenicillins usage in acute tonsillopharyngitis (6% vs. 16%); lower ATB 
ratio in acute sinusitis (43% vs. 57%); however high ratio of macrolides was the 
problem across all groups. Higher prescription quality and lower ATB costs correlated 
together. There was signiﬁcant decrease of ATB costs induced by one pediatrician 
during six years of the project (−50%). CONCLUSIONS: S-MedDial project repre-
sents an option for increase of antibiotics prescription quality using the prescribing 
practitioners’ education. Analysis of prescription habits is suitable not only for cost 
control but also for antibiotics prescription implications on resistance trends. Long-
term integrated educational program leads to prescription habits change and better 
quality of care.
PRS46
TEN YEAR TRENDS IN PRESCRIPTION OF CHRONIC OBSTRUCTIVE 
PULMONARY MEDICATION AMONG ADULTS FROM 1996 TO 2005
Mehta H, Patel J, Parikh R, Aparasu RR, Sherer J
University of Houston, Houston, TX, USA
OBJECTIVES: Many guidelines were released during the past decade which tried to 
explain appropriate drug use for patients diagnosed with COPD. Medication use in 
COPD is also associated with issues related to adherence and side effects. The purpose 
of this study was to determine trends in prescription of COPD drugs in ambulatory 
setting and assess the rate of change in different drug classes. METHODS: We com-
bined National Ambulatory Care Settings (NAMCS) and National Hospital Ambula-
tory Care Settings (NHAMCS) data from year 1996 to 2005. For trend analysis, data 
were stratiﬁed in 2-year periods. All adult visits with only primary diagnosis of COPD 
(ICD-9-CM: 491, 492, 496) were included in analysis and drug categories were identi-
ﬁed using National Drug Codes. Descriptive analysis was carried out to determine 
patterns in drug prescription across years and four separate multivariate logistic 
models, dependent variable being drug class and independent variable being year, were 
constructed to identify rate of change in drug use across years while controlling for 
age, race, sex and smoking status. RESULTS: From 1996–97 to 2004–05, total COPD 
visits have been increased from 0.59% to 0.77%; Prescription of anticholinergics and 
inhaled corticosteroids increased (17.47% to 33.48% and 12.63% to 35.19% respec-
tively), whereas beta-agonist had no upward trend (29.46% to 29.53%). In year 
1996–97, beta-agonist was the highly prescribed drug (29.46%) whereas in 2004–05, 
anticholinergics (33.48%) and inhaled corticosteroids (35.19%) were the top pre-
scribed medications. From year 1996 to 2005, prescription of anticholinergics (OR-
1.088; CI-1.029–1.151) and inhaled corticosteroids (OR-1.132; CI-1.065–1.203) 
increased, beta agonist use has decreased (OR-0.916; CI-0.866–0.969) whereas there 
was no change for systemic corticosteroids (OR-1.034; CI-0.979–1.092). CONCLU-
SIONS: Overall drug utilization for COPD is increasing steadily. Use of bronchodila-
tors is increasing which is in accordance with Global initiative for Chronic Obstructive 
Lung Disease (GOLD) guidelines. Corticosteroid use which is increasing should be 
based on risk to beneﬁt ratio.
RESPIRATORY-RELATED DISORDERS – Conceptual Papers & Research on 
Methods
PRS47
COMPARING RISK ADJUSTMENT MODELS: PROPENSITY SCORE 
MATCHING, STANDARD REGRESSION ANALYSIS AND INSTRUMENTAL 
VARIABLE METHOD
Baser O1, Dysinger A2, Baser E2
1STATinMED Research / University of Michigan, Ann Arbor, MI, USA, 2STATinMED 
Research, Ann Arbor, MI, USA
OBJECTIVES: To compare three common risk adjustment models when estimating 
health care costs. METHODS: Using data from U.S. claims databases, the effect of 
treatment on total health care expenditures among asthma patients was estimated. 
Reimbursement amounts were dollars paid by the health plan to the provider including 
patient co-payments and deductibles. Doctors’ prescribing patterns were used as an 
instrumental variable for treatment choice. Propensity score matching was employed 
using the nearest neighbor matching algorithm. Generalized linear model was used as 
an alternative risk adjustment technique. RESULTS: Patients treated with control 
medication were younger, more likely to live in the northeast and south of the United 
States and have a higher Charlson comorbidity score, Elixhauser score and chronic 
disease score relative to patients treated with reliever medication. The difference 
between one year health care costs for reliever and controller medication was $2,345 
by propensity score matching, $2,195 by generalized linear model, and $2,997 by 
instrumental variable approach. The difference was statistically signiﬁcant. CONCLU-
SIONS: After adjusting for patient clinical and demographic characteristics, controller 
medication was less costly than reliever medication. The choice of risk adjustment was 
important. The technique that controlled for both observed and unobserved biases 
(instrumental variable technique) provided a difference of almost 30% higher than 
the other techniques.
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ASSESSING THE TIME-DEPENDENT NATURE OF COMORBIDITY 
INFLUENCE IN COPD
Kiri VA1, MacKenzie G2
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OBJECTIVES In most outcome studies, comorbidity inﬂuence is modelled as constant 
with inherent assumptions that the duration of the condition does not inﬂuence 
prognosis and the effect persists. We challenge these assumptions as we demonstrate 
the time-dependent nature of the inﬂuence of certain comorbidities on patient survival. 
METHODS A retrospective cohort of 23,881 patients aged 50+ in the UK-GPRD at 
time of incident COPD diagnosis between 1990 and 1998 provided an appropriate 
setting. Each death patient was matched to as many survivors from the same practice 
as possible, of same age, sex and COPD duration. Some 18 binary comorbidities 
measured at the time of death were analysed in relation to mortality. Using conditional 
logistic regression model, we estimated hazard ratio (HR) for each comorbidity, 
adjusted for key baseline characteristics in two different models: In model A, we 
treated comorbidities as constant variables, whilst in B, we stratiﬁed each into two 
time-dependent categorical variables. We retained interactions between comorbidities 
which were signiﬁcant. RESULTS Some 2938 dead patients were matched to 5792 
survivors. We found evidence of time-dependent effects on risk for all but peripheral 
vascular disease and diabetes. Only in model B did we ﬁnd evidence for peptic ulcer, 
moderate/severe liver disease and hemiplagia/paraplagia. The liver disease effect was 
signiﬁcant only in those diagnosed within a year of death (HR > 15; p = 0.0162), 
where as the hemiplagia/paraplagia effect was found only in those diagnosed over a 
year ago (HR > 1.6; p = 0.0163). CONCLUSIONS To adequately adjust for comorbid-
ity inﬂuence in outcome studies, we recommend stratiﬁcation of each comorbidity on 
the basis of its duration (at start of follow-up for a cohort, or at time of outcome for 
a case-control study) to test for possible time-dependent effect. Adopting such 
approach as part of the exploratory analysis may improve the model and lead to more 
accurate estimations
PRS49
COMPARISON OF TWO METHODS FOR COVARIATE ADJUSTMENT 
WHEN ASSESSING HEALTH OUTCOMES IN THE U.S. HOSPITAL 
INPATIENT SETTING
Garvert W, Gemmen E, Bharmal M
Quintiles, Falls Church, VA, USA
OBJECTIVES: Demonstrate the differences in results from the use of two different 
methods for covariate adjustment when calculating differences in outcomes between 
groups. METHODS: The 2006 Nationwide Inpatient Sample hospital database was 
analyzed to estimate the clinical and economic impact to U.S. hospitals of air leaks 
during post-operative pulmonary surgery. For all stays with pulmonary surgery, length 
of stay (LOS), total charges, and in-hospital mortality rates were compared between 
stays including an air leak vs. stays without an air leak, while using two different 
methods to adjust for covariates: 1) multivariate regression analysis (ordinary least 
square regression for LOS and total charges, and logistic regression for in-hospital 
mortality) while controlling for age, gender, and hospital region; 2) 1:1 matched case-
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controls based on age, gender, and hospital region. RESULTS: The 2006 NIS con-
tained a total of 15,748 unweighted hospital inpatient stays with pulmonary surgery, 
2,412 of which included an air leak and 13,336 were non-air leak stays. Patients with 
pulmonary surgery stays including an air leak were older than those patients without 
an air leak (61.5 yrs vs. 60.2 yrs; p = 0.0002), were less likely to be from the Northeast 
(17.3% vs. 21.52%, p < 0.0001) and more likely to be from the South (44.9% vs. 
41.9%, p = 0.0010). Multivariate regressions (N = 15,748) yielded incremental LOS, 
total charges and odds of in-hospital mortality due to the presence of an air leak of 
3.5 days (SE = 0.15), $14,272 ($1,198.2), and +26.0% (95% CI:-0.34%, 64.2%), 
respectively. The 1:1 case-control matching approach (N = 2,364 matched pairs) 
yielded differences in LOS, total charges and odds of in-hospital mortality of 3.6 days 
(0.14), $14,011 ($1,207.8) and +17.2% (−0.17%, 66.2%), respectively. CONCLU-
SIONS: In evaluating differences in health outcomes in a U.S. hospital inpatient 
database, adjusting for covariates using a matching scheme yielded only a modest 
impact vs. multivariate regression analysis.
SYSTEMIC DISORDERS/CONDITIONS – Clinical Outcomes Studies
PSY1
CONCORDANCE IN PATIENT REPORTED MEASURES OF OPIOID-
RELATED SIDE EFFECTS COLLECTED FROM CHECKLIST VERSUS 
OPEN-TEXT FORMAT QUESTIONS
Abouzaid S1, Benson C2, Chow W2, Kim M2
1Ortho-McNeil Janssen Scientiﬁc Affairs, LLC, Titusville, NJ, USA, 2Ortho-McNeil Janssen 
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OBJECTIVES: Compare two different formats—checklist and open text— of ques-
tions soliciting opioid-related side effects (OSEs) with respect to the proportion of 
patients reporting OSEs and the number of OSEs reported. METHODS: Data from 
Day 3 assessment of the oxycodone IR users registry (OUR), an ongoing, prospective, 
multicenter registry of patients age 18–85 with acute episodes of non-malignant pain 
requiring treatment with oxycodone IR for >5 days were used. Patients who completed 
two types of OSEs assessments on Day3 were included in the analysis. The ﬁrst assess-
ment is in an open-text format allowing for identiﬁcation of up to 7 symptoms. The 
second is in a checklist format listing 14 symptoms along with questions about the 
frequency and degree of distress associated with each. Correspondences between 
patient responses solicited through the two different formats were examined using 
descriptive statistics. Interim data were used for the current analysis. The entire registry 
patient population will be analyzed in early 2010. RESULTS: Among 182 patients 
examined for this analysis, mean (±SD) age was 49.3 (±12.7) years, 60.2% were female 
and 74.3% white. Oxycodone IR was most commonly prescribed for injury/trauma 
(30.5%), back/neck pain (28.8%), and arthritis (18.1%). The proportion of patients 
reporting any OSEs in the checklist was nearly two-fold that in the open text (98.9 
vs 53.6%; p < 0.001). Patients, on average, reported 4.1 (SD = 6.3) OSEs on the 
checklist vs 1.3 (SD = 1.6) on the open-text question (p < 0.001). Signiﬁcantly more 
events were reported in the checklist vs open text question for each OSE examined (p 
< 0.001). OSEs reported to be frequent and bothersome on the checklist were signiﬁ-
cantly more likely to appear in the open text compared to infrequent and mild 
symptoms. CONCLUSIONS: Frequency and extent of OSE reporting may vary by the 
format of questions administered. Caution is warranted in collecting, reporting, and 
comparing symptom data from different studies.
PSY2
PREDICTORS OF OBESITY MEDICATION USE IN AMBULATORY 
SETTING: NAMCS 2006–07 ANALYSIS
Mehta H, Parikh R, Patel J, Abughosh S
University of Houston, Houston, TX, USA
OBJECTIVES: To determine the independent predictors of prescription of anti-obesity 
medication for adult patients diagnosed with obesity and to determine association of 
insurance status on anti-obesity medication prescription. METHODS: The data source 
was 2006 and 2007 National Ambulatory Medical Care Survey, a national survey of 
U.S. non-institutionalized population. All adult patients >= 18 years diagnosed with 
obesity (ICD-9-CM: 278.00) were included in the study for analysis. Weighted descrip-
tive analysis and multivariate logistic regression were carried out to identify patterns 
of drug use and independent predictors of at least one prescription of anti-obesity 
medication, adjusting for age, race, sex, region, insurance status, co-morbidity, coun-
seling and MSA. RESULTS: An estimated 113 million adult visits had diagnosis of 
obesity in the 2 years. Of these, 5.79% visits resulted in anti-obesity medication 
prescription. In multivariate model, males (OR—0.244 CI: 0.128–0.463), were less 
likely to receive anti-obesity medication prescription as compared to females. Patient 
visits covered by private or public insurance were less likely to receive prescription 
(OR—0.056 CI: 0.021–0.146 and OR—0.080 CI: 0.034–0.189 respectively). Increase 
in age was associated with decreased (OR—0.976 CI: 0.962–0.990) likelihood of 
receiving anti-obesity medication prescription. Adults who received obesity counseling 
were almost four times more likely to receive anti-obesity medication prescription 
(OR—3.730 CI: 1.878–7.407). Physician type, MSA, co-morbidity status, race and 
region were not signiﬁcantly associated in the ﬁnal multivariate model. CONCLU-
SIONS: Study ﬁnding suggests that adequate coverage for anti-obesity medications 
might not be available for obese adults. Obesity is a harbinger for other chronic 
diseases like CHF, diabetes, hypertension, arthritis and some cancers; thus reducing 
access to obesity medications might lead to an overall increase in the health care 
expenditure in United States. Obesity counseling seems to promote medication use 
which might be due to an increased awareness among obese patients.
PSY3
CENTRAL VENOUS LINE INFECTIONS IN PATIENTS WITH 
HEMOPHILIA AND HOME CARE SERVICES
Tankersley MA1, Blankenship CS2, Doedyns A2, Lewis N2, Johnson N3, Tang J1
1Accredo Health Group, Inc, Memphis, TN, USA, 2Accredo’s Hemophilia Health Services, 
Nashville, TN, USA, 3Accredo’s Hemphilia Health Services, Nashville, TN, USA
OBJECTIVES: Patients with hemophilia require frequent administration of intrave-
nous clotting factor to prophylactically or episodically control bleeding from injury 
or activity. Severe patients may require the placement of a central venous access device 
due to the frequency of infusions or poor peripheral venous access. Subsequent central 
venous line infections are potentially life threatening and may require hospitalization 
which consumes excessive health care resources. Catheter infection events cost up to 
$29,000 per episode for acutely ill patients and can be much higher when cost of 
clotting factor is included. Costs of these events include intravenous antibiotics and 
device replacement. The study purpose was to evaluate incidence of central venous 
access device infections in people receiving clotting factor in the home setting. 
METHODS: A retrospective, longitudinal analysis of patients receiving intravenous 
clotting factor using data from the Accredo electronic medical record was conducted. 
Inclusion criteria were the presence or placement of a central venous access device and 
the dispensing of at least one clotting factor prescription during the study period. 
Patients were followed from October 1, 2008 through September 30, 2009. The 
patient reported infection rate was deﬁned as the number of bloodstream infections 
per 1000 patient catheter days. RESULTS: The sample size of 475 patients reviewed 
encompassed 131,916 patient catheter days during the study period with average 
catheter dwell time of 278 days. The central line infection rate was 0.53 per 1000 
patient catheter days with minimal month to month variation. CONCLUSIONS: 
Intravenous administration of clotting factor via a central venous access device is an 
important alternative infusion option for select patients with bleeding disorders. 
Patients can be well managed in the home on intravenously administered factor via 
central venous access devices. This is an important contribution to limited literature 
on central line infections in the home setting.
PSY4
DAILY AVERAGE CONSUMPTION ANALYSIS OF LOW BACK PAIN AND 
OSTEOARTHRITIS PATIENTS USING OXYMORPHONE EXTENDED 
RELEASE AND OXYCODONE HYDORCHLORIDE CONTROLLED 
RELEASE TABLETS IN A COMMERCIALLY INSURED POPULATION
Berner T, Puenpatom A, Lai PC, Thomson H, Hartry A
Endo Pharmaceuticals, Chadds Ford, PA, USA
OBJECTIVES: This study assessed the daily average consumption (DACON) patterns 
for oxymorphone extended release tablets and oxycodone hydrochloride controlled 
release tablets in the treatment of low back pain (LBP) and osteoarthritis (OA). 
METHODS: Observational, retrospective study of a US commercially insured health 
plan cohort, which included pharmacy and medical claims for patients with ≥1 diag-
nosis of LBP and/or OA. Subjects with OA and or LBP were identiﬁed by ICD-9-CM 
codes following classiﬁcations1,2,3 previously employed. The primary outcome measure 
for the analysis was DACON which was calculated by dividing the total number of 
tablets dispensed by the total number of days supply for equianalgesic4 doses of each 
medication, as deﬁned by an oxymorphone ER : oxycodone HCl CR ratio of 1:2. 
Patient demographic data were assessed and outcomes were stratiﬁed by age, gender, 
and region comparing users who had claim activity for 2 or more of the two medica-
tions for at least 30 days prior to and 90 days after the index date. The t-test was 
used to compare mean differences between the two populations for continuous vari-
ables. Multivariate analysis was conducted as a sensitivity analysis in controlling for 
age, gender, and region heterogeneity. RESULTS: Data analyzed encompassed 
approximately 25 million covered lives for the period January 2006 to March 2009. 
DACON across all tablet strengths for oxymorphone ER was 2.2 compared to 2.6 
for oxycodone CR (p < 0.01). For each formulations maximum strength tablet, oxy-
morphone ER 40 mg DACON was 2.6, compared to 3.7 for oxycodone CR 80 mg 
(p < 0.01). All statistically signiﬁcant results for patients with LBP and/or OA had 
higher DACONs for oxycodone CR than for oxymorphone ER. CONCLUSIONS: 
These ﬁndings imply that health plan drug policies may need to take into consideration 
overall usage patterns, patient demographics, and medical diagnoses for long-acting 
opioids in addition to tablet costs when making formulary decisions.
PSY5
A META-ANALYSIS OF EFFICACY AND SAFETY OF PARECOXIB IN 
ORTHOPEDICS SURGERY
Villasis-Keever MA1, Rendón-Masías ME1, Escamilla-Nuñez A1, Mould-Quevedo JF2
1Instituto Mexicano del Seguro Social, Mexico City, Mexico, Mexico, 2Pﬁzer S.A. de C.V., 
México City, Mexico
OBJECTIVES: The aim of this study was to conduct a meta-analysis of randomized 
clinical trials (RCTs) to determine effectiveness and safety of parecoxib as an analgesic 
option for adult patients in orthopedics surgery. METHODS: All meta-analysis esti-
mations were performed with RCTs based on trials with similar parecoxib doses (20 
or 40 mg) and by type of comparator (placebo or other drugs). Effectiveness was 
assessed with patient global treatment evaluation, consuming rescue drug rate, pain 
intensity at 24 or 48 h after surgery and morphine consume after surgery; safety with 
the frequency and type of adverse events(AE). RCT were searched in December 2008 
